What is CJC-1295?
CJC-1295 is a synthetic peptide analog of Growth Hormone-Releasing Hormone (GHRH). It is designed to stimulate the anterior pituitary gland to release endogenous human Growth Hormone (hGH). It exists in two primary forms: CJC-1295 with DAC (Drug Affinity Complex), which binds to albumin in the blood to dramatically extend its half-life, and CJC-1295 without DAC (commonly referred to as Modified GRF 1-29), which has a much shorter duration of action.
How does CJC-1295 work?
CJC-1295 binds to GHRH receptors on the pituitary gland, mimicking the action of natural GHRH. This triggers a pulsatile release of the body's own growth hormone, which in turn stimulates the liver to produce Insulin-Like Growth Factor 1 (IGF-1). Because it stimulates endogenous production rather than introducing synthetic hGH, it preserves the body's natural feedback loops and pulsatile release patterns.
Primary Documented Uses
- Promoting fat loss and increasing lean muscle mass
- Enhancing physical recovery, skin elasticity, and cellular repair
- Improving deep sleep quality and overall vitality
- Supporting natural growth hormone production in aging individuals
Research Summary
Clinical studies show that CJC-1295 (particularly the DAC version) can increase mean plasma growth hormone levels by 2- to 10-fold and IGF-1 levels by 1.5- to 3-fold for extended periods. It has been shown to improve lean body mass, enhance protein synthesis, and support deeper slow-wave sleep. It is generally well-tolerated, with mild injection-site reactions being the most common side effect.
Legal and Regulatory Status
CJC-1295 is not FDA-approved for human clinical use. In 2023, the FDA added CJC-1295 to Category 2 of the bulk drug substances list, banning 503A compounding pharmacies from compounding it. It is banned by WADA and is legally sold strictly for laboratory research.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 is A synthetic GHRH analog that stimulates the pituitary gland to release growth hormone, often paired with DAC to extend its half-life.
How does CJC-1295 work?
CJC-1295 binds to GHRH receptors on the pituitary gland, mimicking the action of natural GHRH. This triggers a pulsatile release of the body's own growth hormone, which in turn stimulates the liver to produce Insulin-Like Growth Factor 1 (IGF-1). Because it stimulates endogenous production rather than introducing synthetic hGH, it preserves the body's natural feedback loops and pulsatile release patterns.
What does research say about CJC-1295?
Clinical studies show that CJC-1295 (particularly the DAC version) can increase mean plasma growth hormone levels by 2- to 10-fold and IGF-1 levels by 1.5- to 3-fold for extended periods. It has been shown to improve lean body mass, enhance protein synthesis, and support deeper slow-wave sleep. It is generally well-tolerated, with mild injection-site reactions being the most common side effect.
Is CJC-1295 FDA-approved or legally available?
CJC-1295 is not FDA-approved for human clinical use. In 2023, the FDA added CJC-1295 to Category 2 of the bulk drug substances list, banning 503A compounding pharmacies from compounding it. It is banned by WADA and is legally sold strictly for laboratory research.